Just a guess but if a large international company and it's big backer are thinking about behaving themselves now then maybe AZN might be that large international player that granted favorable lease back terms to NWBO while Mr. Woodford remains in time out for a little while longer while everything gets worked out. Great Britain would not necessarily want another foreign company developing a game changing technology right in their back yard when they have their own home grown company just down the road so to speak. I think Roche and perhaps others will set up shop with NWBO elsewhere because a 10,000 patient capacity is not really all that much when thinking about multiple indications eventually. Best wishes.
Market Data 
Markets 
AI
